Ianalumab is a medicine given by injection to help people with autoimmune diseases like rheumatoid arthritis (RA), Sjögren's disease (SjD), or systemic lupus erythematosus (SLE). This study compares two ways of giving ianalumab: a 2 mL auto-injector (AI) and a 1 mL pre-filled syringe (PFS). The goal is to see if both methods work similarly and are safe. The study lasts up to 88 weeks, with an optional extended period up to 176 weeks.
Key points:
- The study has three parts: screening (up to 4 weeks), treatment (up to 72 weeks), and follow-up (up to 176 weeks).
- Participants must be adults (18-70 years old) with specific autoimmune diseases and meet other health criteria.
- Participants will not receive live vaccines and must use contraception if they can become pregnant.
How understandable was the trial content above?
Hard to understand
Easy to understand